Compare MTCH & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTCH | CORT |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.7B |
| IPO Year | 2004 | 2001 |
| Metric | MTCH | CORT |
|---|---|---|
| Price | $37.92 | $114.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $35.17 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ 17.82 | N/A |
| EPS | ★ 1.37 | 0.09 |
| Revenue | ★ $3,487,197,000.00 | $761,407,000.00 |
| Revenue This Year | $2.15 | $26.08 |
| Revenue Next Year | $3.82 | $26.98 |
| P/E Ratio | ★ $27.22 | $1,228.89 |
| Revenue Growth | 0.22 | ★ 12.79 |
| 52 Week Low | $28.81 | $28.66 |
| 52 Week High | $41.40 | $122.21 |
| Indicator | MTCH | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 64.64 |
| Support Level | $37.19 | $76.41 |
| Resistance Level | $39.36 | $122.21 |
| Average True Range (ATR) | 1.05 | 5.13 |
| MACD | -0.26 | -0.09 |
| Stochastic Oscillator | 32.40 | 75.23 |
Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. It generates the majority of its revenue from the Tinder segment.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.